None of the 29 investors followed here reported a position in SSMXY in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Alan Armstrong Sen. OK | 1 | +$8.0K | Bought Mar 30, 26 | |
| Josh Gottheimer NJ05 | 1 | 3 | −$16.0K | Trimmed Dec 5, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Mar 30, 26 | Alan Armstrong Sen. OK | Self | Buy | $1,001 - $15,000 | Jul 21, 26 (113d) | Report |
| Dec 5, 25 | Josh Gottheimer NJ05 | Joint | Sell (part) | $1,001 - $15,000 | Jan 14, 26 (40d) | |
| Sep 22, 25 | Josh Gottheimer NJ05 | Joint | Buy | $1,001 - $15,000 | Oct 15, 25 (23d) | |
| Aug 21, 25 | Josh Gottheimer NJ05 | Joint | Sell (part) | $1,001 - $15,000 | Sep 5, 25 (15d) | |
| Apr 9, 25 | Josh Gottheimer NJ05 | Joint | Sell (part) | $1,001 - $15,000 | May 14, 25 (35d) |
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for SSMXY.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.1 | -0.7 | -7.4 | 0.3 | 0.0 | 3.3 | 10.7 | 22.8 | -4.7 | 0.9 | +20.7% | ||
| 2025 | 4.3 | -5.1 | 4.9 | -2.7 | -9.2 | 3.8 | -6.2 | -23.0 | -2.9 | -9.0 | -14.8 | 3.0 | −46.7% |
| 2024 | -1.8 | 2.3 | -7.2 | -7.5 | 7.1 | -5.9 | 1.6 | 18.1 | 1.7 | -5.6 | 14.1 | -13.5 | −1.2% |
| 2023 | 9.9 | -9.6 | 9.6 | -2.2 | 1.9 | 4.5 | -0.6 | -21.6 | -10.5 | 1.3 | 14.9 | 0.4 | −7.7% |
| 2022 | -30.1 | -16.0 | -8.7 | -9.6 | 1.9 | -10.5 | 16.9 | -12.4 | -12.9 | 0.5 | 13.6 | -1.6 | −55.6% |
| 2021 | -2.2 | -11.1 | 3.7 | -7.4 | 3.7 | 14.2 | 0.0 | -4.6 | 10.1 | -0.8 | 0.7 | 8.7 | +12.7% |
| 2020 | 5.2 | -12.5 | 14.0 | -3.2 | 14.7 | -3.4 | 0.2 | 13.9 | 9.9 | -1.8 | 10.7 | 15.3 | +76.9% |
| 2019 | 17.2 | 8.6 | -0.1 | -5.6 | 20.9 | -5.7 | 11.9 | -12.8 | 5.9 | -3.3 | 6.7 | -1.9 | +43.3% |
| 2018 | 0.2 | 4.9 | 9.8 | -2.6 | 0.8 | 3.8 | 2.3 | -8.7 | -0.5 | -18.8 | -23.9 | -11.0 | −39.9% |
| 2017 | 2.9 | -3.4 | 5.7 | -0.1 | -2.2 | 0.5 | -3.8 | 7.7 | 3.3 | 7.0 | 11.5 | 3.4 | +36.0% |
| 2016 | -1.1 | -2.7 | 0.7 | 1.1 | 14.5 | -6.3 | 1.8 | -6.9 | 14.7 | -5.7 | -12.5 | -4.8 | −10.2% |
| 2015 | -0.0 | 20.2 | 3.7 | -0.9 | 5.0 | 2.8 | 8.6 | -6.6 | -12.6 | 8.2 | 9.3 | 3.3 | +44.5% |
| 2014 | -7.2 | 8.1 | 9.1 | -3.0 | 11.1 | 7.2 | 4.0 | -0.9 | 4.1 | 7.8 | 1.0 | 1.8 | +50.6% |
| 2013 | 3.9 | 10.0 | 16.4 | 5.7 | 1.3 | 0.9 | -2.2 | -10.7 | 11.2 | 3.1 | -1.3 | -9.1 | +29.1% |
| 2012 | -6.2 | 0.0 | 0.0 | 0.0 | 27.5 | -4.2 | 9.0 | 7.1 | 3.8 | -2.3 | -3.7 | 1.5 | +32.6% |
| 2011 | 0.0 | 2.1 | +2.1% |
No analyst coverage for this instrument.
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing. The company also provides Caresphere, an ICT solution, which integrates and analyzes real time various data managed through testing instruments and clinical testing information systems, and supports the efficient operation of clinical laboratories; and involved in the medical robotics business. It serves products and services to medical institutions, clinical laboratories, animal hospitals, and research institutes. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.